Nevrargenics Ltd. Information

Our vision is to employ new dual-acting retinoic acid receptor modulators (RAR-M) as the basis for developing a new rational effective treatment approach for ALS and FTD and meet that huge unmet need. We also plan to expand the indications to target the wider range of neurodegenerative diseases like Alzheimer's and Parkinson's.